Drupal.behaviors.print = function(context) {window.print();window.close();}>
As MaterniT21 Drives Spike in Diagnostic Revenue, Sequenom Predicts 25K Tests Sold in 2012
March 14, 2012
As MaterniT21 Drives Spike in Diagnostic Revenue, Sequenom Predicts 25K Tests Sold in 2012
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Sequenom Runs More Than 13K T21 Tests in Q2; Plans to Expand Capacity in US and Overseas
August 1, 2012 / Clinical Sequencing News
Sequenom Plans Sample-Prep Automation, Increased Multiplexing to Double MaterniT21 Capacity
May 9, 2012 / Clinical Sequencing News
Sequenom Launches MaterniT21 Down Syndrome Test as LDT, Publishes Clinical Validation Study
October 19, 2011 / Clinical Sequencing News
With Clinical Validation Study Complete, Sequenom Moves Ahead with 2012 Launch of T21 Test
May 10, 2011 / Clinical Sequencing News
Sequenom Provides Update on Patent Litigation; Plans to Bring NC Lab Online in 30 to 45 Days
June 5, 2013 / Clinical Sequencing News